Bank of India Flexi Cap Fund
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity-related securities across various market capitalisation.
Growthvine rating: 5/5 — ranked #3 of 53 in category.
Fund basics
| Category | Equity: Flexi Cap |
|---|
| NAV | ₹37.56 (as of 2026-10-01) |
|---|
| AUM | ₹2,786 Cr |
|---|
| Expense ratio | 1.68% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Alok Singh |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 3 months |
|---|
Performance & risk
| 5-year annualised return | 14.52% |
|---|
| Sharpe ratio | 0.77 |
|---|
| Standard deviation | 18.78% |
|---|
| Max drawdown | −23.98% |
|---|
| Alpha | 6.81 |
|---|
| Beta | 1.11 |
|---|
Over 5 years, captured 120.7% of Nifty 500's upside and 100.5% of its downside.
Market cap allocation
| Large cap | 43.4% |
|---|
| Mid cap | 17.4% |
|---|
| Small cap | 39.2% |
|---|
Concentration
| Top 5 holdings | 17.7% |
|---|
| Top 10 holdings | 30.5% |
|---|
| Total holdings | 65 |
|---|
| Index overlap | 24.5% |
|---|
| Active share | 75.5% |
|---|
Top holdings
- State Bank Of India — 5.0%
- TREPS — 4.5%
- ICICI Bank Ltd. — 3.9%
- Hindustan Aeronautics Limited — 3.0%
- Sky Gold And Diamonds Limited — 2.9%
- QUALITY POWER ELECTRICAL EQUIPMENTS LIMITED — 2.8%
- Balrampur Chini Mills Ltd. — 2.8%
- Mankind Pharma Limited — 2.7%
- Dr. Reddys Laboratories Ltd. — 2.5%
- Bharti Airtel Ltd. — 2.5%
Top sectors
- Banking & Financial — 16.5%
- Pharma & Biotech — 7.6%
- Automobile — 7.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 6.3% | Q1 (Top) | #1 of 50 |
| 2025 | −0.3% | Q4 (Bottom) | #35 of 43 |
| 2024 | 29.0% | Q1 (Top) | #4 of 42 |
| 2023 | 37.9% | Q1 (Top) | #2 of 36 |
| 2022 | −0.9% | Q3 | #17 of 30 |